Certara to Participate in the Jefferies Global Healthcare Conference
Radnor, PA — May 29, 2024 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraMay 29, 2024
Secondary Intelligence™ Demo
Discover how Secondary Intelligence™ can support your compound assessments by predicting off-target activities and potential…
CertaraMay 24, 2024
Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice
Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's…
CertaraMay 22, 2024
CERTAINTY Europe
GREATER CERTAINTY IN DRUG DEVELOPMENT Certainty by Certara offers exclusive access to Certara experts, industry leaders, and…
CertaraMay 22, 2024
Clinical Pharmacology & Model-Informed Drug Development Insights for Targeted Radiation Therapies
Targeted radiation therapies (TRT) deliver cytotoxic radiation selectively to tumors. In recent years, oncology drug…
CertaraMay 22, 2024
Certara Appoints New Chief Human Resources Officer & General Counsel
RADNOR, PA – May 21, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraMay 21, 2024
Accelerating the Progress of Kinase Inhibitors in Oncology
The potential of PBPK modeling in answering key questions around these drugs. Hannah Jones, PhDMasoud…
CertaraMay 20, 2024
Unlocking Efficiency in Formulation Development and Approvals with MIFD & Simcyp Biopharmaceutics [APAC Webinar]
Biopharmaceutical professionals can gain a significant edge in formulation development by attending this free webinar…
CertaraMay 16, 2024
Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates
In recent years, oncology drug developers have invested in antibody-drug conjugates (ADCs). These targeted therapies…
CertaraMay 10, 2024
